Co-diagnostics Inc (CODX)

$1.12

+0.02

(+1.82%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.10
    $1.16
    $1.12
    downward going graph

    1.79%

    Downside

    Day's Volatility :5.17%

    Upside

    3.45%

    downward going graph
  • $0.98
    $1.73
    $1.12
    downward going graph

    12.4%

    Downside

    52 Weeks Volatility :43.29%

    Upside

    35.26%

    downward going graph

Returns

PeriodCo-diagnostics IncSector (Health Care)Index (Russel 2000)
3 Months
-0.9%
6.5%
0.0%
6 Months
-12.7%
7.1%
0.0%
1 Year
-24.14%
9.8%
0.0%
3 Years
-88.12%
14.2%
-20.2%

Highlights

Market Capitalization
37.6M
Book Value
$2.51
Earnings Per Share (EPS)
-1.31
PEG Ratio
0.0
Wall Street Target Price
2.0
Profit Margin
0.0%
Operating Margin TTM
-2192.86%
Return On Assets TTM
-26.4%
Return On Equity TTM
-41.16%
Revenue TTM
6.7M
Revenue Per Share TTM
0.23
Quarterly Revenue Growth YOY
-22.3%
Gross Profit TTM
28.7M
EBITDA
-41.8M
Diluted Eps TTM
-1.31
Quarterly Earnings Growth YOY
0.31
EPS Estimate Current Year
-1.33
EPS Estimate Next Year
-1.15
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Co-diagnostics Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 78.57%

Current $1.12
Target $2.00

Company Financials

FY18Y/Y Change
Revenue
39.9K
↑ 420.9%
Net Income
-6.3M
↓ 9.88%
Net Profit Margin
-15.7K%
↑ 75113.61%
FY19Y/Y Change
Revenue
215.0K
↑ 438.63%
Net Income
-6.1M
↓ 3.23%
Net Profit Margin
-2.8K%
↑ 12891.09%
FY20Y/Y Change
Revenue
74.6M
↑ 34579.9%
Net Income
42.5M
↓ 799.91%
Net Profit Margin
56.98%
↑ 2880.16%
FY21Y/Y Change
Revenue
97.9M
↑ 31.3%
Net Income
36.7M
↓ 13.7%
Net Profit Margin
37.45%
↓ 19.53%
FY22Y/Y Change
Revenue
34.2M
↓ 65.04%
Net Income
-14.2M
↓ 138.84%
Net Profit Margin
-41.61%
↓ 79.06%
FY23Y/Y Change
Revenue
991.5K
↓ 97.1%
Net Income
-35.3M
↑ 148.15%
Net Profit Margin
-3.6K%
↓ 3522.06%
Q4 FY22Q/Q Change
Revenue
1.4M
↓ 72.49%
Net Income
-21.9M
↑ 1509.44%
Net Profit Margin
-1.6K%
↓ 1536.3%
Q1 FY23Q/Q Change
Revenue
602.0K
↓ 57.05%
Net Income
-5.8M
↓ 73.73%
Net Profit Margin
-956.11%
↑ 606.91%
Q2 FY23Q/Q Change
Revenue
197.8K
↓ 67.14%
Net Income
-8.9M
↑ 54.96%
Net Profit Margin
-4.5K%
↓ 3552.76%
Q3 FY23Q/Q Change
Revenue
2.5M
↑ 1142.18%
Net Income
-6.0M
↓ 32.93%
Net Profit Margin
-243.47%
↑ 4265.4%
Q4 FY23Q/Q Change
Revenue
3.6M
↑ 44.69%
Net Income
-14.7M
↑ 145.34%
Net Profit Margin
-412.82%
↓ 169.35%
Q1 FY24Q/Q Change
Revenue
252.7K
↓ 92.89%
Net Income
-9.3M
↓ 36.55%
Net Profit Margin
-3.7K%
↓ 3271.54%
FY18Y/Y Change
Total Assets
1.6M
↓ 66.69%
Total Liabilities
2.6M
↑ 221.75%
FY19Y/Y Change
Total Assets
2.2M
↑ 42.63%
Total Liabilities
478.1K
↓ 81.7%
FY20Y/Y Change
Total Assets
71.2M
↑ 3115.65%
Total Liabilities
4.5M
↑ 849.8%
FY21Y/Y Change
Total Assets
160.0M
↑ 124.65%
Total Liabilities
25.6M
↑ 462.89%
FY22Y/Y Change
Total Assets
123.1M
↓ 23.09%
Total Liabilities
8.6M
↓ 66.48%
FY23Y/Y Change
Total Assets
103.6M
↓ 15.79%
Total Liabilities
17.6M
↑ 105.85%
Q4 FY22Q/Q Change
Total Assets
123.1M
↓ 16.74%
Total Liabilities
8.6M
↓ 33.57%
Q1 FY23Q/Q Change
Total Assets
117.0M
↓ 4.95%
Total Liabilities
6.4M
↓ 25.67%
Q2 FY23Q/Q Change
Total Assets
112.8M
↓ 3.59%
Total Liabilities
9.4M
↑ 47.14%
Q3 FY23Q/Q Change
Total Assets
108.7M
↓ 3.65%
Total Liabilities
9.2M
↓ 1.89%
Q4 FY23Q/Q Change
Total Assets
103.6M
↓ 4.63%
Total Liabilities
17.6M
↑ 91.84%
Q1 FY24Q/Q Change
Total Assets
86.7M
↓ 16.38%
Total Liabilities
8.3M
↓ 52.83%
FY18Y/Y Change
Operating Cash Flow
-4.1M
↑ 27.05%
Investing Cash Flow
-380.3K
↑ 100.91%
Financing Cash Flow
1.9M
↓ 68.4%
FY19Y/Y Change
Operating Cash Flow
-5.5M
↑ 35.42%
Investing Cash Flow
-435.2K
↑ 14.44%
Financing Cash Flow
5.9M
↑ 214.65%
FY20Y/Y Change
Operating Cash Flow
28.2M
↓ 609.77%
Investing Cash Flow
-5.8M
↑ 1238.17%
Financing Cash Flow
19.7M
↑ 234.44%
FY21Y/Y Change
Operating Cash Flow
41.1M
↑ 45.86%
Investing Cash Flow
4.1M
↓ 170.37%
Financing Cash Flow
450.4K
↓ 97.72%
FY22Y/Y Change
Operating Cash Flow
6.6M
↓ 84.01%
Investing Cash Flow
-58.2M
↓ 1519.19%
Financing Cash Flow
-14.0M
↓ 3215.91%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.0M
↓ 458.56%
Investing Cash Flow
-53.3M
↓ 1224.82%
Financing Cash Flow
-1.2M
↓ 88.29%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.5M
↑ 37.15%
Investing Cash Flow
-10.6M
↓ 80.05%
Financing Cash Flow
-482.2K
↓ 60.39%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.2M
↓ 5.27%
Investing Cash Flow
13.2M
↓ 224.49%
Financing Cash Flow
-555.7K
↑ 15.25%
Q3 FY23Q/Q Change
Operating Cash Flow
-6.6M
↑ 26.59%
Investing Cash Flow
3.2M
↓ 76.05%
Financing Cash Flow
-166.3K
↓ 70.07%

Technicals Summary

Sell

Neutral

Buy

Co-diagnostics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Co-diagnostics Inc
Co-diagnostics Inc
-17.29%
-12.7%
-24.14%
-88.12%
-17.29%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Co-diagnostics Inc
Co-diagnostics Inc
4.96
NA
0.0
-1.33
-0.41
-0.26
NA
2.51
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Co-diagnostics Inc
Co-diagnostics Inc
Sell
$37.6M
-17.29%
4.96
0.0%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Co-diagnostics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.55M → 252.74K (in $), with an average decrease of 92.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -14.67M → -9.31M (in $), with an average increase of 57.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 65.8%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 157.0%

Institutional Holdings

  • Vanguard Group Inc

    5.69%

  • Renaissance Technologies Corp

    1.92%

  • BlackRock Inc

    1.60%

  • Geode Capital Management, LLC

    0.94%

  • Bridgeway Capital Management, LLC

    0.87%

  • Kestra Advisory Services, LLC

    0.48%

Company Information

co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are

Organization
Co-diagnostics Inc
Employees
155
CEO
Mr. Dwight H. Egan
Industry
Health Technology

Discover More

FAQs